Evidence from an equilibrium dialysis technique for the binding of lead with transfusion gelatin.

W. Malik,M. Jindal

Abstract:

What problem does this paper attempt to address?

1024 SURWEY: Treatment of Excessive Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcomes

Gregory Parks,Lothar Burghaus,Graham Eglit,Iresha Abeynayake,Samantha Floam,Yaroslav Winter

DOI: https://doi.org/10.1093/sleep/zsae067.01024

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Solriamfetol (Sunosi®), a dopamine/norepinephrine reuptake inhibitor with agonistic properties at TAAR1 and 5HT1A receptors, is a wake-promoting agent approved to treat excessive daytime sleepiness (EDS) associated with narcolepsy (75–150 mg/day) or obstructive sleep apnea (OSA; 37.5–150 mg/day). Real world data on solriamfetol safety and efficacy remains limited. Here we review real-world survey results to evaluate dosing/titration strategies and outcomes on EDS in patients with OSA, narcolepsy, and the pooled (OSA + narcolepsy) population. Methods Data from a retrospective chart review (SURWEY) by German physicians who prescribed solriamfetol for EDS associated with narcolepsy or OSA were analyzed. Inclusion criteria have been previously reported. Initiation and titration strategies (new-to-therapy, changeover, add-on) and Epworth Sleepiness Scale (ESS) scores are reported for each diagnosis and the pooled population to examine EDS as a symptom independent of etiology. Results Differences in baseline age, sex, and body mass index were observed for OSA (n=83) and narcolepsy (n=71) patients. Most common initiation strategy was new-to-therapy (n=63/83; 74.7%) for OSA and changeover (n=44/71; 62.0%) for narcolepsy. Patients with a final dose ≥150 mg/day were n=16 (19.5%), n=31 (45.6%), and n=47 (26.1%) for OSA, narcolepsy, and pooled, respectively. At initiation, mean±SD ESS scores were similar: 16.0±3.2 (OSA), 17.6±3.1 (narcolepsy), 16.7±3.2 (pooled). Mean±SD change from baseline in ESS scores at final follow-up were –5.4±3.6 (OSA), –4.5±3.2 (narcolepsy), –5.0±3. 5 (pooled). In the pooled analysis, ESS scores improved by 5.5, 4.7, and 4.4 in new-to-therapy, changeover, and add-on groups, respectively. In the changeover group, ESS scores improved by 5.7, 4.7, 4.6, and 4.0 points in patients who switched to solriamfetol from modafinil (n=13), stimulants (n=3), pitolisant (n=16), or unknown medication (n=21), respectively, while patients who added solriamfetol to pitolisant (n=13) or modafinil (n=3) improved by 4.4 and 3.3 points, respectively. Common adverse effects were headache, insomnia, and decreased appetite. Conclusion These real-world data describe the use of solriamfetol in patients with EDS in OSA or narcolepsy. Titration strategies differed by primary etiology but changes in ESS scores were similar. Although sample size was limited, clinically meaningful improvements in ESS scores were observed with solriamfetol regardless of switch/add-on medication. Support (if any) Axsome Therapeutics, Jazz Pharmaceuticals, Pharmanovia

neurosciences,clinical neurology
0970 Real-world Use of Solriamfetol for Excessive Daytime Sleepiness in Patients Reporting Anxiety or Depression

Ulf Kallweit,Heike Benes,Lothar Burghaus,Graham Eglit,Iresha Abeynayake,Samantha Floam,Gregory Parks,Yaroslav Winter

DOI: https://doi.org/10.1093/sleep/zsae067.0970

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Psychiatric comorbidities are common in patients with excessive daytime sleepiness (EDS) from narcolepsy or obstructive sleep apnea (OSA). Real-world efficacy and safety data of wake promoting agents in these populations is limited. Solriamfetol (Sunosi®), a dopamine/norepinephrine reuptake inhibitor that activates TAAR1 and 5HT1A receptors, is approved to treat EDS associated with narcolepsy or OSA. Solriamfetol clinical trials excluded and the prescribing information caution against use in patients with severe psychiatric comorbidities, so limited data exists for this population. Here we describe real world use of solriamfetol in German patients with narcolepsy or OSA who self-reported depression/anxiety (yes/no response) at baseline. Methods We performed a retrospective chart review (SURWEY) using data from German physicians who prescribed solriamfetol to patients with EDS associated with narcolepsy or OSA and at a stable dose for ≥6 weeks. Comorbidities, including anxiety/depression, were documented with background information at baseline. Results Of the 154 patients, n=48 (31.2%) reported anxiety and/or depression (OSA, n=23/83 [27.7%], narcolepsy, n=25/71 [35.2%]). Most patients (≥85%) reported no additional psychiatric, neurological, or sleep disorder. Regardless of primary etiology, baseline mean±SD Epworth Sleepiness Scale (ESS) scores were generally similar in patients with (OSA, 16.0±2.8; narcolepsy, 17.9±3.6) and without (OSA, 16.0±3.3; narcolepsy, 17.5±2.9) anxiety/depression. Overall, mean±SD decreases in ESS scores were 4.6±3.2 and 5.2±3.6 with and without anxiety/depression, respectively; and similar in OSA (5.2±3.1 vs 5.5±3.9), narcolepsy (3.9±3.2 vs 4.9±3.3). Ninety percent of patients achieved ≥2-point reduction in ESS scores from baseline and patients (≥89%) and physicians (≥91%) reported improvement in EDS with solriamfetol, which were both similar across primary etiologies and anxiety/depression presence. Anxiety/depression data was not collected at follow-up. Common adverse events were headache, insomnia, and decreased appetite, which generally occurred at similar rates regardless of reported anxiety/depression. Conclusion These real-world data describe solriamfetol treatment outcomes in narcolepsy or OSA patients who did and did not self-report anxiety/depression. Regardless of anxiety/depression, ESS scores improved, and most patients and physicians reported improved EDS. Our findings are consistent with clinical trial results and suggest that solriamfetol is effective in managing EDS symptoms in this population regardless of common psychiatric comorbidities. Support (if any) Axsome Therapeutics, Jazz Pharmaceuticals, Pharmanovia

neurosciences,clinical neurology
Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy

Michael J Thorpy,Danielle Hyman,Gregory S Parks,Abby Chen,Catherine Foley,Beth Baldys,Diane Ito,Haramandeep Singh

DOI: https://doi.org/10.1016/j.clinthera.2022.08.012

Abstract:Purpose: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved (in the United States and European Union) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75-150 mg/d) or obstructive sleep apnea (OSA) (37.5-150 mg/d). This study characterized real-world titration strategies for patients with narcolepsy (with or without comorbid OSA) initiating solriamfetol therapy. Methods: This virtual, descriptive study included a retrospective medical record review and qualitative survey. US-based physicians prescribing solriamfetol for EDS associated with narcolepsy or OSA participated. Data are reported for patients with narcolepsy with or without comorbid OSA (OSA alone reported separately). On the basis of medical record review, titration strategies were classified de novo (EDS medication naive), transition (switched or switching from existing EDS medication[s] to solriamfetol), or add-on (adding solriamfetol to current EDS medication[s]). The survey included open-ended questions regarding a hypothetical patient-a 32-year-old woman with narcolepsy (Epworth Sleepiness Scale score of 8) treated with 35 mg/d of amphetamine and 6 g per night of sodium oxybate who experiences non-use-limiting adverse events from amphetamine. Findings: Twenty-six physicians participated: 23 provided data from 70 patients with narcolepsy (type 1, n = 24; type 2, n = 46; mean [SD] age, 40 [11] years; 57% female; 6 with comorbid OSA), and 26 responded to the hypothetical patient scenario. From the medical record review, solriamfetol therapy initiation was de novo for 19 of 70 patients (27%), transition for 31 of 70 patients (44%), and add-on for 20 of 70 patients (29%). Efficacy profile of solriamfetol was the primary reason for de novo (12 of 19 [63%]), transition (18 of 31 [58%]), and add-on (19 of 20 [95%]) initiation. Most (86%) initiated use of solriamfetol at 75 mg/d and were stable at 150 mg/d (76%). Most (67%) had 1 dose adjustment, reaching a stable dose over a median (range) of 14 (1-60) days. Physicians most often considered EDS severity (44%) when titrating. Among transitioning patients, 14 of 22 (64%) using wake-promoting agents discontinued their use abruptly, and 5 of 9 (56%) using stimulants were tapered off. At data collection, 90% continued to take solriamfetol. Regarding the hypothetical patient scenario, most physicians (81%) thought solriamfetol was appropriate, highlighting tolerability issues with current treatment and lack of symptom control as drivers for switching; however, 3 physicians (12%) did not think solriamfetol was appropriate, noting current symptoms were not severe enough and/or symptoms could be managed by increasing sodium oxybate dose; 2 (8%) thought it would depend on other factors. Physicians emphasized managing withdrawal symptoms while maintaining EDS symptom control when titrating off a stimulant and starting solriamfetol therapy. Implications: In a real-world study, physicians initiated solriamfetol therapy at 75 mg/d for most patients with narcolepsy, adjusted dosages once, tapered stimulants, and abruptly discontinued therapy with wake-promoting agents.
1215 Adjunctive Use of Solriamfetol in Pediatric Excessive Daytime Sleepiness: A Single Center Experience

Robin Varughese,Christine Palladino,Sanjeev Kothare

DOI: https://doi.org/10.1093/sleep/zsae067.01215

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Solriamfetol (Sunosi) has been FDA-approved for adults aged 18 years or older particularly for excessive daytime sleepiness (EDS) associated with obstructive sleep apnea or narcolepsy. It works as a selective norepinephrine and dopamine reuptake inhibitor to promote wakefulness in this particular population. The benefit of this medication, compared to other medications to promote wakefulness, is that it is a non-stimulant medication. It has also been noted to have significant long-term efficacy rates for adults with EDS. Given the success of solriamfetol in the adult population, it has been trialed on EDS patients within the pediatric population. The purpose of this study is to better summarize the safety, efficacy, dosing, and side effect profile of pediatric patients using solriamfetol. Report of case(s) We performed a retrospective analysis of 11 pediatric patients who have been placed on solriamfetol and studied the improvement of daytime sleepiness with this intervention. Typical up-titration of the medication and monitoring for failure of improvement of sleepiness required a follow up period of at least 3 months. We collected the following data points: gender, weight, age, diagnosis (OSA or narcolepsy), medications, sleep study findings, and subjective endorsement of improvement based on Likert scale with increments of 0-25%, 26-50%, 51-75%, and 76-100% improvement. Our results demonstrated >50% responsiveness in 18% (2/11) of the patients in our cohort with 27% (3/11) of patients having some improvement of their excessive daytime sleepiness by 26-50%. Only 18% (2/11) patients reported adverse effects of headaches or increased anxiety with none of the patients reporting SJS-like rashes or insomnia. All patients tolerated the 150 mg daily dosing. No interactions were noted with patients taking OCPs. Conclusion Solriamfetol demonstrates similar tolerability, safety and side effect profile within the pediatric population when compared to the adult population and may provide additional benefit in refractory cases of EDS at maximal doses. More studies are needed to validate these observations. Support (if any)

neurosciences,clinical neurology
1007 Solriamfetol on Cognition in Obstructive Sleep Apnea with Excessive Daytime Sleepiness and Impaired Cognition

Hans Van Dongen,Eileen Leary,Graham Eglit,Christopher Drake,Richard Bogan,Judith Jaeger

DOI: https://doi.org/10.1093/sleep/zsae067.01007

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Cognitive impairment is a burdensome symptom in many patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). Solriamfetol (Sunosi®) is a dopamine/norepinephrine reuptake inhibitor, with agonistic properties at TAAR1 and serotonin 1A receptors, approved to treat EDS associated with OSA (37.5–150 mg/day). We evaluated the effect of solriamfetol on subjective cognitive function by examining overall scores and individual cognitive complaint and functional items of the British Columbia-Cognitive Complaints Inventory (BC-CCI). Methods SHARP was a randomized, double-blind, placebo-controlled, crossover trial in participants with impaired cognition associated with OSA and EDS. Participants received solriamfetol for 2 weeks (75 mg for 3 days, then 150 mg/day), and placebo for 2 weeks, separated by a 1-week wash out. Items of the BC-CCI included forgetfulness/memory problems, slow thinking speed, trouble expressing thoughts, trouble finding the right word, poor concentration, trouble figuring things out, and vocational, family/friends, and social/recreational functioning. Mixed models with repeated measures were used to examine differences in changes from baseline between placebo and solriamfetol. Results The SHARP study enrolled 59 participants (ages 52.2±10.7y; 36% female). Baseline overall BC-CCI scores were 11.4±2.5 (mean±SD); scores were comparable in participants randomized to the solriamfetol/placebo (n=30; mean=11.4) versus placebo/solriamfetol (n=29; mean=11.4) crossover sequences. Overall BC-CCI scores showed greater reduction from baseline (ie, more improvement in subjective cognitive function) after solriamfetol compared with place bo (P=0.002; Cohen’s d=0.45). Baseline scores on individual BC-CCI items were generally similar for participants randomized to solriamfetol/placebo versus placebo/solriamfetol. Solriamfetol led to greater reductions from baseline compared with placebo in poor concentration (P=0.007; d=0.37), slow thinking speed (P=0.009; d=0.36), trouble finding the right word (P=0.042; d=0.28), trouble figuring things out (P=0.030; d=0.30), and forgetfulness/memory problems (P=0.013; d=0.34). Trouble expressing thoughts approached significance (P=0.077; d=0.24). No significant differences were found for vocational, family/friends, and social/recreational functioning (P>0.05). Conclusion Consistent with previous reports showing improvement on objective cognitive measures, solriamfetol led to significant subjective improvements overall, and particularly in subjective cognitive domains that may be related to memory, executive functioning, and processing speed. Solriamfetol can improve subjective cognitive functioning in participants with impaired cognition associated with OSA and EDS. Support (if any) Axsome Therapeutics, Jazz Pharmaceuticals

neurosciences,clinical neurology
Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database

Beili He,Wei Zheng

DOI: https://doi.org/10.1016/j.heliyon.2024.e38450

IF: 3.776

2024-09-25

Heliyon

Abstract:Solriamfetol is a selective dopamine and noradrenalin reuptake inhibitor applied in adult patients with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA). However, the post-marketing safety profile of solriamfetol in large number of people was unrevealed. The purpose of our study is to unravel solriamfetol's adverse events (AEs) in real-world to refine medication safety using Food and Drug Administration Adverse Event Reporting System (FAERS) database. We derived the data associated with solriamfetol from FAERS between 2019 and 2023, and removed the duplicated entries. We evaluated the disproportionality of solriamfetol's AEs by reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multi-item gamma Poisson shrinker (MGPS). Among 8,846,085 AE reports, 1659 recorded solriamfetol as the 'primary suspected (PS)'. 74 significant disproportionality preferred terms (PTs) were retained across 27 organ systems. Moreover, 16 unexpected AEs not mentioned in the FDA label of solriamfetol were identified. Our findings provided the post-marketing safety profile of solriamfetol, highlighting potential solriamfetol's AEs. Further researches are significant to define the causality between solriamfetol and newly identified AEs.
Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy

Atul Malhotra,Patrick J Strollo Jr,Jean-Louis Pepin,Paula Schweitzer,Gert Jan Lammers,Jan Hedner,Susan Redline,Dan Chen,Patricia Chandler,Shay Bujanover,Kingman Strohl

DOI: https://doi.org/10.1016/j.sleep.2022.08.005

Abstract:Objectives: This analysis characterized changes in weight in participants with obstructive sleep apnea (OSA) or narcolepsy treated with solriamfetol (Sunosi™) 37.5 (OSA only), 75, 150, or 300 mg/d. Methods: In two 12-week, randomized, placebo-controlled trials and one 1-year open-label extension study, changes in weight were evaluated from baseline to end of study (week 12 or week 40 of the open-label extension [after up to 52 weeks of solriamfetol treatment]) in participants with OSA or narcolepsy. Results: After 12 weeks of solriamfetol treatment, median percent change in weight from baseline across all solriamfetol doses was -0.84%, compared with 0.54% for placebo, in participants with OSA; and -0.07%, compared with 3.08% for placebo, in participants with narcolepsy. After up to 52 weeks of solriamfetol treatment, overall median percent change in weight from baseline was -1.76%, which showed a dose-dependent pattern (75 mg, 0.57%; 150 mg, -1.2%; 300 mg, -2.5%). Results were similar in subgroups of participants with OSA or narcolepsy, with overall median percent changes in weight of -2.2% and -1.1%, respectively. After up to 52 weeks of solriamfetol treatment, the percentage of participants with weight loss ≥5% relative to baseline was 25.7% overall and increased in a dose-dependent manner (75 mg, 4.5%; 150 mg, 17.3%; 300 mg, 32.4%). Results were similar among subgroups of participants with OSA or narcolepsy, with 26.4% and 24.2% of participants experiencing weight loss ≥5%, respectively. No weight-related treatment-emergent adverse events were serious. Conclusions: Solriamfetol treatment was associated with decreases in body weight in a dose-related manner.
{4,4′-Dimethoxy-2,2′-[1,1′-(ethane-1,2-diyldinitrilo)diethylidyne]diphenolato}nickel(II) hemihydrate

H. Fun,R. Kia

DOI: https://doi.org/10.1107/S1600536808023362

2008-07-31

Abstract:In the title complex, [Ni(C20H22N2O4)]·0.5H2O, the NiII ion is in a slightly distorted square-planar geometry involving an N2O2 atom set of the tetradentate Schiff base ligand. The asymmetric unit contains one molecule of the complex and half a water solvent molecule. The solvent water molecule lies on a crystallographic twofold rotation axis. An intermolecular O—H⋯O hydrogen bond forms an R 2 1(4) ring motif involving a bifurcated hydrogen bond to the phenolate O atoms of the complex. In the crystal structure, molecules are linked by π–π stacking interactions, with centroid–centroid distances in the range 3.5310 (11)–3.7905 (12) Å, forming extended chains along the b axis. In addition, there are Ni⋯Ni and Ni⋯N interactions [3.4404 (4)–4.1588 (4) and 3.383 (2)–3.756 (2) Å, respectively] which are shorter than the sum of the van der Waals radii of the relevant atoms. Further stabilization of the crystal structure is attained by weak intermolecular C—H⋯O and C—H⋯π interactions.
0640 Magnitude of Improvement in Excessive Daytime Sleepiness with the Once-at-Bedtime Oxybate for Narcolepsy

Clete Kushida,Michael Thorpy,Anne Morse,John Harsh,Luis Ortiz,Thomas Roth,Yves Dauvilliers,Jennifer Gudeman

DOI: https://doi.org/10.1093/sleep/zsae067.0640

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Safety and efficacy of once-nightly sodium oxybate (ON-SXB; LUMRYZTM) were investigated in the phase 3 REST-ON trial (NCT02720744). Results demonstrated statistically significant improvements in the secondary endpoint of excessive daytime sleepiness (EDS) measured using the Epworth Sleepiness Scale (ESS; P< 0.001 vs placebo) at all doses tested beginning at week 2 (post hoc analysis, ON-SXB 6 g vs placebo at week 2). The objective of this post hoc analysis was to assess the magnitude of improvement in the patient-reported outcome of EDS following treatment with ON-SXB. Methods Participants aged ≥16 years with narcolepsy type 1 (NT1) or 2 (NT2) were randomized 1:1 to ON-SXB or placebo. Doses were 4.5 g week 1; 6 g weeks 2−3; 7.5 g weeks 4−8; and 9 g weeks 9−13. Median (interquartile range [IQR]) ESS scores were assessed for each dosing period. Results Mean age of participants was 31.2 years, 68% were female, 75.5% were white, and 76.4% had NT1. The modified intent-to-treat population included 190 participants (ON-SXB, n=97; placebo, n=93). Baseline median (IQR) ESS scores were 17 (14−19) for ON-SXB and 18 (15−21) for placebo. At week 1, median (IQR) ESS scores were 16 (12−18) for ON-SXB 4.5 g vs 17 (13−20) for placebo. At week 3 (ON-SXB 6 g), median (IQR) ESS scores were 14 (10−18) vs 17 (14−20) for placebo. At week 8 (ON-SXB 7.5 g), median (IQR) ESS scores were 12 (8−16) vs 15.5 (12−20) for placebo. At week 13, median (IQR) ESS scores for ON-SXB 9.0 g were 9.5 (6.0−15.0) vs 15 (11−19) for placebo. Conclusion Treatment with ON-SXB resulted in clinically meaningful improvements in EDS with doses ≥6 g, as median ESS scores were within the range considered normal (≤10) at the end of the trial. ON-SXB is considered an effective intervention in treatment of EDS for patients with narcolepsy with a once-at-bedtime dose. Support (if any) Avadel Pharmaceuticals

neurosciences,clinical neurology
0649 Samelisant Improves the Symptoms of Excessive Daytime Sleepiness in Narcolepsy: Results from a Phase-2 Study

Ramakrishna Nirogi,Jyothsna Ravula,Pradeep Jayarajan,Vinod Kumar Goyal,Vijay Benade,Satish Jetta,Anil Shinde,Dhanunjay Dogiparti,Ramkumar Subramanian,Ilayaraja Kalaikadhiban,Venkat Jasti

DOI: https://doi.org/10.1093/sleep/zsae067.0649

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Narcolepsy is a lifelong sleep disorder characterized by a classic tetrad of excessive daytime sleepiness (EDS) with irresistible sleep attacks, cataplexy, hypnagogic hallucination, and sleep paralysis. The currently available treatments suffer from major limitations like side effects, modest efficacy or they must be prescribed in combination. Samelisant (SUVN-G3031) is a potent and selective histamine 3 receptor inverse agonist. In orexin knockout mice, samelisant produced wake-promoting and anticataplectic effects suggesting its potential therapeutic utility in the treatment of narcolepsy. Safety and tolerability studies in animals and healthy human volunteers suggest a favorable risk/benefit profile for samelisant. Methods Samelisant had been evaluated as monotherapy in a Phase-2 proof of concept study in the USA and Canada for the treatment of EDS in patients with narcolepsy (ClinicalTrials.gov Identifier: NCT04072380). Patients diagnosed with narcolepsy as per ICSD-3 criteria, aged between 18 to 65 years with an Epworth Sleepiness Scale (ESS) score of ≥12 and mean Maintenance of Wakefulness Test (MWT) time of < 12 min were recruited in the study. A total of 190 patients were randomized into 3 treatment arms (placebo, samelisant 2 mg and samelisant 4 mg) in 1:1:1 ratio and received either placebo or samelisant, once daily for 2 weeks. The primary efficacy endpoint was change in ESS score from baseline to Day 14. Secondary endpoints were changes from baseline to week 2 in Clinical Global Impression - Severity (CGI-S) and MWT scores. The medical monitor and the data safety monitoring committee monitored safety throughout the study. Results The baseline characteristics and demographics were consistent with the general narcolepsy population and equally distributed between treatment groups. The study met the pre-specified primary efficacy endpoint. In comparison against placebo, samelisant as monotherapy demonstrated statistically significant (p< 0.024) and clinically meaningful reduction (-2.1 point) in EDS measured by ESS. Samelisant was generally safe and well tolerated. Conclusion Samelisant holds promise as a monotherapy treatment of EDS in narcolepsy. Support (if any)

neurosciences,clinical neurology
Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea

Terri E. Weaver,Diane M. Menno,Morgan Bron,Ross D. Crosby,Susan Morris,Susan D. Mathias

DOI: https://doi.org/10.1007/s11325-020-02270-3

2021-01-04

Sleep And Breathing

Abstract:Abstract Purpose This study estimated thresholds for clinically important responses and minimally important differences for two indicators of improvement for the 10-item version of the functional outcomes of sleep questionnaire (FOSQ-10). Methods Participants with excessive daytime sleepiness with narcolepsy or obstructive sleep apnea received 12 weeks of solriamfetol treatment. Participants completed the FOSQ-10 and other patient-reported outcome measures, including the single-item patient global impression of change (PGI-C) assessment. Clinicians completed the single-item clinician global impression of change (CGI-C) for each participant. Data from the two studies were analyzed separately, both without regard to treatment assignment. In total, 690 participants (47% female, mean age 48 years, 77% Caucasian, 91% from North America) were enrolled. Two clinically important changes, defined as a minimally important difference and a clinically important response, were determined using distribution and anchor-based analyses. A receiver operating characteristic analysis was used to determine the optimal FOSQ-10 change threshold. Results Spearman correlations between change in FOSQ-10 scores and PGI-C and CGI-C were − 0.57 and − 0.49 for participants with narcolepsy and − 0.42 and − 0.37 for participants with obstructive sleep apnea. Receiver operating characteristic analysis suggested minimally important difference and clinically important response estimates of 1.7 and 2.5 and 1.8 and 2.2 points in narcolepsy and obstructive sleep apnea, respectively. Conclusions Minimally important difference and clinically important response estimates for the FOSQ-10 for adults with excessive daytime sleepiness in narcolepsy or obstructive sleep apnea will be helpful for interpreting changes over time and defining a clinical responder. ClinicalTrials.gov identifiers NCT02348593 (first submitted January 15, 2015) and NCT02348606 (first submitted January 15, 2015)

clinical neurology,respiratory system
Use of Esketamine Nasal Spray in Patients with Treatment‐Resistant Depression in Routine Practice: A Real‐World French Study

Ludovic Samalin,Lila Mekaoui,Maud Rothärmel,Anne Sauvaget,Clotilde Wicart,Julien Dupin,Vanessa Cohignac,Emeline Gaudre-Wattinne

DOI: https://doi.org/10.1155/2024/7262794

IF: 8.128

2024-07-18

Depression and Anxiety

Abstract:Background. The efficacy and safety of esketamine nasal spray (ESK) were established in registration trials in patients with treatment‐resistant depression (TRD). This French real‐world study aimed to describe the treatment patterns, effectiveness, and safety of ESK in TRD patients over a 12‐month follow‐up. Materials and Methods. This study used secondary data from patient files of hospital‐based psychiatrists and started during the first French patient early access to ESK. The response and remission rates with ESK were analyzed using the total score of the Montgomery–Åsberg Depression Rating Scale (MADRS). The time to first treatment response and work resumption were described (Kaplan–Meier method). Adverse events (AEs) were analyzed. Results. Prior to ESK initiation, the 157 analyzed patients (age ≤ 65 years, 82.8%; female, 66.2%) had depression for 10.5 years (median, IQR, 4.2–21.2) and received a median of 6 (3–8) previous treatment lines. At ESK initiation, the mean ± SD total MADRS score was 32.1 ± 7.7. At that time, ESK was combined with antidepressants (93.6% of patients; SNRI, 65.0%; SSRI, 57.3%) and/or other potentiation strategy (63.1%; atypical antipsychotics, 36.3%; lithium, 25.6%; antiepileptics, 21.7%). During the 12‐month follow‐up, 125 patients (79.6%) discontinued ESK. The median duration of ESK treatment was 19.4 weeks (IQR, 4.4–40.1). At 1 month after ESK initiation, 40.2% of still treated patients met criteria for clinical response and 19.7% for remission (median time to response, 5.7 weeks; 95% CI (4.1–8.4)). 82.6% of active patients were on sick leave at ESK initiation; the work resumption rate was 24% (13%–40%) 12 weeks later. AEs were reported in 68.6% of patients, serious AEs in 17.2%, and AEs leading to ESK discontinuation in 14.6%. Conclusion. These real‐world effectiveness and safety data were consistent with findings from previous clinical trials, describing the real‐life clinical experience of patients receiving ESK and confirming that ESK has its place in therapy for the treatment of TRD.

psychiatry,psychology, clinical
1021 Samelisant: Clinician and Patient Global Impression from a Double-Blind, Phase-2 Study in Patients with Narcolepsy

Ramakrishna Nirogi,Pradeep Jayarajan,Vinod Kumar Goyal,Jyothsna Ravula,Satish Jetta,Anil Shinde,Vijay Benade,Renny Abraham,Veera Raghava Chowdary Palacharla,Santosh Kumar Pandey,Abdul Rasheed Mohammed,Venkat Jasti

DOI: https://doi.org/10.1093/sleep/zsae067.01021

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Samelisant (SUVN-G3031) is a potent and selective histamine 3 receptor (H3R) inverse agonist. Samelisant exhibited desired pharmacokinetic properties in rodents and healthy human volunteers. Preclinical studies in orexin knockout mice demonstrated wake promoting and anticataplectic effects of samelisant. To confirm the preclinical findings, Samelisant was evaluated as monotherapy for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy with or without cataplexy. The primary endpoint was changes in the Epworth Sleepiness Scale (ESS) scores. Clinician and Patient Global Impression for EDS were assessed as secondary and exploratory endpoints. Methods Two doses of samelisant (2 and 4 mg) were evaluated as a monotherapy in a Phase-2 study for the treatment of EDS in subjects with narcolepsy (ClinicalTrials.gov Identifier: NCT04072380). Subjects diagnosed with narcolepsy as per ICSD-3 criteria, aged between 18 to 65 years with an ESS score of ≥12 and mean Maintenance of Wakefulness Test (MWT) time of < 12 min were recruited in the study. A total of 190 subjects were randomized into 3 treatment arms (placebo, samelisant 2 mg and samelisant 4 mg) in 1:1:1 ratio and received either placebo or samelisant once daily for 2 weeks. The primary efficacy endpoint was the change in ESS score from baseline to week 2. Clinical Global Impression – Severity (CGI-S) was a secondary endpoint, whereas change in Patient Global Impression – Change (PGI-C) and Clinical Global Impression of Change (CGI-C) scores related to EDS were exploratory endpoints. Results At the end of the double-blind period, the samelisant treated groups demonstrated clinically and statistically significant improvements in CGI-S (p< 0.01), PGI-C (p< 0.001) and CGI-C (p< 0.0001) with regards to EDS. The proportion of patients reporting improvement in EDS was significantly higher in the samelisant treatment arms compared to placebo arm. Conclusion Treatment with samelisant as monotherapy resulted in significant improvement in excessive day time sleepiness as assessed by both clinicians and patients. These outcomes support the efficacy of samelisant observed in the primary endpoint, ESS, in patients with narcolepsy with or without cataplexy. Support (if any)

neurosciences,clinical neurology
0637 Composite Response with Once-Nightly Sodium Oxybate: Symptom Improvement in Participants with Narcolepsy Type 1

Luis Ortiz,Thomas Roth,Anne Morse,Michael Thorpy,John Harsh,Clete Kushida,Jennifer Gudeman,Yves Dauvilliers

DOI: https://doi.org/10.1093/sleep/zsae067.0637

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction A novel once-nightly formulation of sodium oxybate (ON-SXB; LUMRYZTM) was investigated in patients with narcolepsy type 1 (NT1) and 2 (NT2) in the phase 3 REST-ON trial (NCT02720744). ON-SXB treatment resulted in statistically significant improvements vs placebo for the coprimary endpoints of change from baseline in mean sleep latency on the Maintenance of Wakefulness test (MWT), Clinical Global Impression-Improvement (CGI-I) rating, and number of weekly cataplexy attacks, as well as the secondary endpoint of improved excessive daytime sleepiness (EDS) using the Epworth Sleepiness Scale (ESS; all P< 0.001 vs placebo). The objective of this post hoc analysis was to assess the proportion of participants with NT1 achieving clinically significant improvement on a composite of these endpoints. Methods Participants (aged ≥16 years with NT1 or NT2) who had continuing presence of EDS (sleep latency < 11 min on the MWT and ESS score >10) and continuing cataplexy (average of 8 episodes/week) were randomized 1:1 to ON-SXB or placebo. Doses were 4.5 g week 1; 6 g weeks 2−3; 7.5 g weeks 4−8; and 9 g weeks 9−13. Clinically significant improvement thresholds per the 2021 American Academy of Sleep Medicine Clinical Practice Guidelines for each endpoint were defined as follows: MWT (2-min improvement), CGI-I (1-point improvement), cataplexy (25% decrease), or ESS (2-point improvement) and examined for each dose. Results Mean age of participants with NT1 was 32.1 years, 72.8% were female, and 76.5% were white. The modified intent-to-treat population included 145 participants with NT1 (ON-SXB, n=73; placebo, n=72). At week 13 (9 g), more participants treated with ON-SXB vs placebo had clinical improvement in ≥2 endpoints (87.3% vs 62.9%; P< 0.01), ≥3 endpoints (76.4% vs 43.5%; P< 0.001), and in all 4 endpoints (47.3% vs 14.5%; P< 0.001). Similar results were observed at all doses. Conclusion These data support the robust clinical efficacy of ON-SXB, a once-at-bedtime oxybate for treatment of cataplexy or EDS in adults with narcolepsy, using multiple disease state metrics compared with placebo. Support (if any) Avadel Pharmaceuticals

neurosciences,clinical neurology
Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA

Mohammad Badran,Clementine Puech,Max B Barrow,Alexandra R Runion,David Gozal

DOI: https://doi.org/10.1016/j.sleep.2023.04.007

Abstract:Background: Obstructive sleep apnea (OSA) is a chronic condition characterized by intermittent hypoxia (IH). Excessive daytime sleepiness (EDS) is a common consequence of OSA and is associated with cognitive deficits and anxiety. Modafinil (MOD) and Solriamfetol (SOL) are potent wake-promoting agents clinically used to improve wakefulness in OSA patients with EDS. Methods: Male C57Bl/6J mice were exposed to either IH or room air (RA) controls during the light phase for 16 weeks. Both groups were then randomly assigned to receive once-daily intraperitoneal injections of SOL (200 mg/kg), MOD (200 mg/kg) or vehicle (VEH) for 9 days while continuing IH exposures. Sleep/wake activity was assessed during the dark (active) phase. Novel object recognition (NOR), elevated-plus maze test (EPMT), and forced swim test (FST) were performed before and after drug treatment. Results: IH exposure increased dark phase sleep percentage and reduced wake bouts lengths and induced cognitive deficits and anxiogenic effects. Both SOL and MOD treatments decreased sleep propensity under IH conditions, but only SOL promoted improvements in NOR performance (explicit memory) and reduced anxiety-like behaviors. Conclusion: Chronic IH, a hallmark feature of OSA, induces EDS in young adult mice that is ameliorated by both SOL and MOD. SOL, but not MOD, significantly improves IH-induced cognitive deficits and promotes anxiolytic effects. Thus, SOL could potentially benefit OSA patients beyond EDS management.
0390 Efficacy of Suvorexant for Insomnia Disorder in Well-controlled Restless Legs Syndrome

John Winkelman,Jordana Zackon

DOI: https://doi.org/10.1093/sleep/zsae067.0390

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Sleep disturbance remains common in patients with a history of Restless Legs Syndrome (RLS), even after RLS symptoms are sufficiently controlled with medication. Multiple potential causes for treatment-refractory sleep disturbance exist, including conditioned insomnia and poor sleep habits due to chronic RLS-related sleep disturbance, and comorbid medical and psychiatric illness. We conducted a placebo-controlled crossover trial to examine the efficacy of suvorexant in improving sleep quality and quantity in patients with well-controlled RLS and persistent insomnia. Methods In this double-blind, randomized, placebo-controlled crossover trial, 34 patients with well-controlled RLS were randomized to placebo or suvorexant (10-20 mg) for 6 weeks, followed by a 2-week washout and then the opposite treatment. Well-controlled RLS was defined as a score of less than 15 on the International Restless Legs Syndrome Study Group Rating Scale (IRLS) and Insomnia Disorder was defined by a self-reported combined Sleep Onset Latency (SOL) and Wake After Sleep Onset (WASO) of greater than 45 minutes and a Total Sleep Time (TST) of less than 7 hours. The primary outcome was actigraphically-derived TST, and secondary outcomes were Insomnia Severity Index (ISI) score and actigraphically-derived WASO. Data for all sleep metrics were collected at baseline and for the last two weeks of each treatment period. Results There were no significant improvements in actigraphically-derived TST (p = 0.58) or WASO (p = 0.99) while taking suvorexant compared to placebo. However, there was a significant reduction in insomnia symptoms, measured by the ISI, while taking suvorexant (p = 0.03). Moreover, exploratory analyses revealed a significant increase in self-reported TST (p = 0.01) and a significant reduction in nightly variability in TST (p = 0.03) while taking suvorexant. The most commonly reported side effect of suvorexant was fatigue (29.4%). Conclusion Though we did not observe a significant change between treatments in our primary endpoint of actigraphically-derived TST, our secondary and exploratory findings revealed promising support for suvorexant’s positive impact on self-reported quantity and quality of sleep in people with well-controlled RLS who continue to suffer from insomnia. Support (if any) Funded by an investigator-initiated grant from Merck Pharmaceuticals.

neurosciences,clinical neurology
0643 Patient Preferences of Sodium Oxybate Treatment for Narcolepsy: RESTORE End-of-Study Survey Data

Akinyemi Ajayi,Emmanuel Mignot,Asim Roy,Bruce Corser,Thomas Stern,J Douglas Hudson,Adrian Santamaria,Brian Abaluck,Jennifer Gudeman

DOI: https://doi.org/10.1093/sleep/zsae067.0643

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Until recently, the only available oxybate therapy options were immediate-release (IR) formulations requiring patients to awaken 2.5 to 4 hours after their first dose to take a second dose. Once-nightly sodium oxybate (ON-SXB; LUMRYZTM) is an extended-release formulation of sodium oxybate that eliminates the need for a middle-of-the-night dose. RESTORE (NCT04451668) was an open-label/switch study that evaluated the safety and tolerability of ON-SXB and surveyed patient preferences for ON-SXB or IR oxybate therapies. Methods Participants were ≥16 years of age with narcolepsy type 1 or 2 who either completed the phase 3 REST-ON trial and were on stable doses of IR oxybate for ≥1 month or oxybate naive. Participants completed end-of-study (EOS) questionnaires to capture their experience with ON-SXB. Results As of November 2023, EOS questionnaire data were available for 89 participants, including 21 participants who completed REST-ON or were oxybate naive and 68 participants who switched from IR oxybate to ON-SXB. In total, 71% (63/89) of responders rated their narcolepsy “much better” or “somewhat better” after initiating ON-SXB. After starting ON-SXB, 75% (67/89) were very satisfied with ON-SXB compared to other treatments they had taken, and 89% (79/89) would recommend ON-SXB to a family member or friend with narcolepsy. Approximately 69% (61/89) of participants found it easier to go through the day without falling asleep, 91% (81/89) were better able to sleep through the night, 64% (57/89) were able to get more done at work or school, and 64% (57/89) were better able to socialize with friends or family. Additionally, 43% (38/89) of responders were able to perform or better perform certain daily activities. Of the participants who switched from IR oxybate to ON-SXB, 91% (62/68) were better able to follow the recommended dosing schedule of ON-SXB. Conclusion These EOS RESTORE data show a high level of satisfaction with ON-SXB, improved symptom control, and a preference for ON-SXB over other treatment options. A majority switching from IR oxybate treatment reported improvement in dosing as directed. Support (if any) Avadel Pharmaceuticals

neurosciences,clinical neurology
0415 Real-world Data and Health-related Quality of Life in Treatment of Chronic Insomnia with Daridorexant

Yaroslav Winter,David Apel,Ingo Fietze

DOI: https://doi.org/10.1093/sleep/zsae067.0415

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Daridorexant was approved by FDA and EMA for the treatment of chronic insomnia. It is a new dual orexin-receptor anatgonist, which demonstrated its clinical efficacy and safety in randomized controlled trials. The real-world data including its influence on the health-related quality of life (HrQol) are not yet available. In this prospective observational study we investigate the influence of daridorexant on HrQol in patients with chronic insomnia. Methods Patients with chronic insomnia diagnosed following the DSM V criteria were included in the observational study in terms of the Mainz Sleep Registry (MAINZ-SLEEPREG). All patients received the standard dosis of daridorexant of 50mg/night. The evaluation of clinical parameters and HrQoL was performed before, as well as three and six months after the initiation of daridorexant. The collected night-time efficacy endpoints included wake time after sleep onset (WASO), latency to persistent sleep (LPS), total sleep time and self-reported total sleep time. The EuroQol5D (EQ5D Index and EQVAS: visual analogue scale) was used to evaluate HrQol. Results Study participants (n=63) were 52.7±11.0 years old and 58.7% of them were females. All applied night-time efficacy measures (WASO, LPF, total sleep and self-reported sleep time) showed a significant improvement by approximately 20-40% at the time points after three and six months (p< 0.05). At the follow-up after three and six months the EQ5D Index values (0.71±0.17 and 0.72±0.15, correspondingly) improved on daridorexant by 18% in comparison to baseline (0.61±0.17, p< 0.05). Similar increase of HrQol was observed on EQVAS (62.2±16.5 at baseline versus 73.9±19.8 and 74.6±18.9, p< 0.05). Conclusion The data from this real-word study shows that daridorexant not only significantly improves the night-time sleep of patients with chronic insomnia but it also increases their HrQol. These findings encourage farther real-world studies to investigate the role of daridorexant in the treatment of chronic insomnia in broader populations. Support (if any)

neurosciences,clinical neurology
Anti-UV activity of Lentinus edodes mycelia extract (LEM).

Toshiyuki Nanbu,T. Matsuta,H. Sakagami,J. Shimada,J. Maki,Toru Makino

2011-09-01

In Vivo

Abstract:BACKGROUND Using our recently established simple method for evaluating protective activity from ultraviolet ray injury (referred to as 'anti-UV activity'), the effectiveness of various antioxidants and plant extracts was investigated. MATERIALS AND METHODS HSC-2 human oral squamous cell carcinoma cells were exposed to UV irradiation (wavelength: 253.7 nm, 6 J/m²) in phosphate-buffered saline (PBS(-)) containing various concentrations of samples and then incubated for 48 hours in regular culture medium to determine the viable cell number by the MTT method. RESULTS Among the representative antioxidants, sodium ascorbate showed the most potent anti-UV activity, whereas catalase and N-acetyl-L-cysteine were inactive. Lentinus edodes mycelia extract (LEM) showed comparable anti-UV activity to sodium ascorbate. Hot water extracts of green tea and coffee, and PET-bottled of green tea extract showed slightly less, but noticeable anti-UV activity. On the other hand, hot water extracts of black tea and Jasmine tea, and PET-bottled of oolong tea, barley tea and Kohki tea were inactive. LEM was separated by gel filtration chromatography into four fractions from high to low molecular weight: polysaccharide, large and small lignin-carbohydrate complexes, and sugars. Anti-UV activity was shown by the lignin-carbohydrate fractions, but not the polysaccharide and sugar fractions. LEM, at high concentration, slightly enhanced the anti-UV activity of sodium ascorbate. CONCLUSION LEM may be applicable as a UV-protective agent.
0650 Safety and Efficacy of KP1077 in a Phase 2, Double-Blind, Randomized Trial in Patients with Idiopathic Hypersomnia

Rene Braeckman,Christopher Drake,Daniel Gallo,Ben Vaughn,Ihab AbdelFattah

DOI: https://doi.org/10.1093/sleep/zsae067.0650

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction KP1077 is under development as an oral medication for the treatment of rare sleep disorders with Excessive Daytime Sleepiness (EDS), including idiopathic hypersomnia (IH). The active ingredient in KP1077 is serdexmethylphenidate (SDX), a prodrug of d-methylphenidate. The objectives of the study were to assess the safety (primary endpoint) and efficacy of KP1077 in patients with IH. Methods Adult patients with IH began KP1077 treatment in a 5-week open-label (OL) titration period. Possible dose levels were 80, 160, 240 and 320 mg/day SDX. Patients were randomized to receive their daily dose either once per day (just before going to sleep), or twice per day (half the daily dose just before going to sleep and half shortly after awakening). After the titration period, patients in each treatment group were randomized to placebo or continued KP1077 (optimized dose) during a 2-week double-blind (DB) withdrawal period. Assessments of safety were based on adverse events (AEs), physical examinations, clinical laboratory tests, vital signs, electrocardiograms, sleep quality, and suicidal ideation. Efficacy assessments included the Epworth Sleepiness Scale (ESS) and Idiopathic Hypersomnia Severity Scale (IHSS). Patients rated their difficulty of waking up in the morning with the Sleep Inertia Visual Analog Scale (SI-VAS) and brain fog throughout the day with an exploratory Brain Fog Scale (BFS). Results Safety and efficacy in the OL titration phase were evaluated in an interim analysis when 22 patients completed the study (target: ≥48 completers). KP1077 was well-tolerated for both treatments and all dose levels, with most frequent AEs of insomnia, headache, and nausea. Most AEs were mild, not leading to early discontinuation. Meaningful clinical improvements in scores of ESS, IHSS, SI-VAS, and BFS were observed in both treatment groups. Mean total ESS scores decreased by >9 points after 5 weeks of OL treatment. Results from all patients in the both the OL titration and DB withdrawal periods will be presented. Conclusion KP1077 was well-tolerated in patients with IH with AEs typical for a central nervous system stimulant. Meaningful clinical improvements of EDS, sleep inertia and brain fog were observed after 5 weeks of OL KP1077. Support (if any) Zevra Therapeutics

neurosciences,clinical neurology

Evidence from an equilibrium dialysis technique for the binding of lead with transfusion gelatin.

1024 SURWEY: Treatment of Excessive Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcomes

0970 Real-world Use of Solriamfetol for Excessive Daytime Sleepiness in Patients Reporting Anxiety or Depression

Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy

1215 Adjunctive Use of Solriamfetol in Pediatric Excessive Daytime Sleepiness: A Single Center Experience

1007 Solriamfetol on Cognition in Obstructive Sleep Apnea with Excessive Daytime Sleepiness and Impaired Cognition

Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database

Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy

{4,4′-Dimethoxy-2,2′-[1,1′-(ethane-1,2-diyldinitrilo)diethylidyne]diphenolato}nickel(II) hemihydrate

0640 Magnitude of Improvement in Excessive Daytime Sleepiness with the Once-at-Bedtime Oxybate for Narcolepsy

0649 Samelisant Improves the Symptoms of Excessive Daytime Sleepiness in Narcolepsy: Results from a Phase-2 Study

Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea

Use of Esketamine Nasal Spray in Patients with Treatment‐Resistant Depression in Routine Practice: A Real‐World French Study

1021 Samelisant: Clinician and Patient Global Impression from a Double-Blind, Phase-2 Study in Patients with Narcolepsy

0637 Composite Response with Once-Nightly Sodium Oxybate: Symptom Improvement in Participants with Narcolepsy Type 1

Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA

0390 Efficacy of Suvorexant for Insomnia Disorder in Well-controlled Restless Legs Syndrome

0643 Patient Preferences of Sodium Oxybate Treatment for Narcolepsy: RESTORE End-of-Study Survey Data

0415 Real-world Data and Health-related Quality of Life in Treatment of Chronic Insomnia with Daridorexant

Anti-UV activity of Lentinus edodes mycelia extract (LEM).

0650 Safety and Efficacy of KP1077 in a Phase 2, Double-Blind, Randomized Trial in Patients with Idiopathic Hypersomnia